更正第 1 段中的公司名称
路透5月21日 - 莫德纳 MRNA.O周三表示，该公司已撤回其针对50岁及以上成人的流感和COVID联合疫苗候选产品的待批申请。
该公司表示，将在今年晚些时候根据其季节性流感实验疫苗后期试验的疫苗疗效数据重新提交申请。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.